Midbrain organoids for in vitro
disease modeling
OrganoTherapeutics is a spin-off project from the University of Luxembourg. OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen for novel compounds which can be therapeutic for different patient sub-groups.
Classic approach
Testing
OT approach
Our expertise
HUMAN-SPECIFIC MODELS
Proprietary 3D models derived from healthy individual and PD patient material
DRUG EFFECTIVENESS
In the minibrains => identification of cellular defects which are missed in conventional methods. The therapeutic potential of compounds can be identified
AUTOMATED ANALYSIS
The screening platform allows fully automated image and data analyses using artificial intelligence approaches
LIBRARY SCREENING
OT has access to unique libraries of chemically defined molecules (LDC) and natural molecules extracted from marine and floral organisms from Australia (Griffith University)
Our team
Javier Jarazo, PHD
Founder
Expert in stem cell models, phenotyping screening and computational data analysis.
JENS SCHWAMBORN, PHD
Founder
Professor at the University of Luxembourg. Neuroscientist expert in stem cell research and Parkinson’s disease research.
ISABEL ROSETY, PHD
LEAD PROJECT SCIENTIST
Expert in 3D cell culture systems and Parkinson’s Disease research.
GEMMA GÓMEZ-GIRÓ
LEAD PROJECT SCIENTIST
Expert in organoid and assembloid systems, neurodegeneration and Parkinson’s Disease research.
SÒNIA SABATÉ-SOLER, PHD
PROJECT MANAGER | BUSINESS DEVELOPER
Expert in stem cell models, organoid and assembloid optimization and neuroinflammation.